A Phase I/ II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Phase of Trial: Phase I/II
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Pazopanib (Primary) ; Bevacizumab
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 5 Feb 2018.
- 04 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.